Dainippon, SanBio Call Time On Stroke Cell Therapy Alliance

SanBio To Press On Despite Trial Failure

 
• By Ian Haydock

Japanese companies agree to discontinue regenerative cell therapy pact after high-profile Phase II failure, but SanBio will move ahead with development and Dainippon will hold onto ex-partner stake for now.

Broken deal
SanBio Considers Options After End Of Cell Therapy Deal • Source: Shutterstock

More from Strategy

More from Business